In: Accounting
| a. What is trend in long-term debt paying ability of over the last three years for CVS - using ratios? | ||||||||||||
| b. What is trend in long-term debt paying ability of over the last three years Walgreens - using ratios? | ||||||||||||
| c. Which company has had better long-term debt paying ability over the last 3 years? Explain with ratios. | ||||||||||||
|
Income Statement for CVS |
||||||||||||
| Revenue | 12/31/2017 | 12/31/2016 | 12/31/2015 |
| Total Revenue | 184,765,000 | 177,526,000 | 153,290,000 |
| Cost of Revenue | 156,220,000 | 148,669,000 | 126,762,000 |
| Gross Profit | 28,545,000 | 28,857,000 | 26,528,000 |
| Operating Expenses | |||
| Research Development | - | - | - |
| Selling General and Administrative | - | - | - |
| Non Recurring | - | - | - |
| Others | - | - | - |
| Total Operating Expenses | - | - | - |
| Operating Income or Loss | 9,517,000 | 10,366,000 | 9,475,000 |
| Income from Continuing Operations | |||
| Total Other Income/Expenses Net | -208,000 | -671,000 | -21,000 |
| Earnings Before Interest and Taxes | 9,309,000 | 9,695,000 | 9,454,000 |
| Interest Expense | 1,041,000 | 1,058,000 | 838,000 |
| Income Before Tax | 8,268,000 | 8,637,000 | 8,616,000 |
| Income Tax Expense | 1,637,000 | 3,317,000 | 3,386,000 |
| Minority Interest | 4,000 | 4,000 | 7,000 |
| Net Income From Continuing Ops | 6,631,000 | 5,320,000 | 5,230,000 |
| Non-recurring Events | |||
| Discontinued Operations | -8,000 | -1,000 | 9,000 |
| Extraordinary Items | - | - | - |
| Effect Of Accounting Changes | - | - | - |
| Other Items | - | - | - |
| Net Income | |||
| Net Income | 6,622,000 | 5,317,000 | 5,237,000 |
| Preferred Stock And Other Adjustments | - | - | - |
| Net Income Applicable To Common Shares | 6,622,000 | 5,317,000 | 5,237,000 |
Income Statement for Walgreens
All numbers in thousands
| Revenue | 8/31/2017 | 8/31/2016 | 8/31/2015 |
| Total Revenue | 118,214,000 | 117,351,000 | 103,444,000 |
| Cost of Revenue | 89,052,000 | 87,477,000 | 76,691,000 |
| Gross Profit | 29,162,000 | 29,874,000 | 26,753,000 |
| Operating Expenses | |||
| Research Development | - | - | - |
| Selling General and Administrative | 23,605,000 | 23,873,000 | 22,085,000 |
| Non Recurring | - | - | - |
| Others | - | - | - |
| Total Operating Expenses | - | - | - |
| Operating Income or Loss | 5,557,000 | 6,001,000 | 4,668,000 |
| Income from Continuing Operations | |||
| Total Other Income/Expenses Net | -11,000 | -261,000 | 1,248,000 |
| Earnings Before Interest and Taxes | 5,546,000 | 5,740,000 | 5,916,000 |
| Interest Expense | 693,000 | 596,000 | 605,000 |
| Income Before Tax | 4,853,000 | 5,144,000 | 5,311,000 |
| Income Tax Expense | 752,000 | 953,000 | 1,032,000 |
| Minority Interest | 808,000 | 401,000 | 439,000 |
| Net Income From Continuing Ops | 4,078,000 | 4,173,000 | 4,220,000 |
| Non-recurring Events | |||
| Discontinued Operations | - | - | - |
| Extraordinary Items | - | - | - |
| Effect Of Accounting Changes | - | - | - |
| Other Items | - | - | - |
| Net Income | |||
| Net Income | 4,078,000 | 4,173,000 | 4,220,000 |
| Preferred Stock And Other Adjustments | - | - | - |
| Net Income Applicable To Common Shares | 4,078,000 | 4,173,000 | 4,220,000 |